» Articles » PMID: 3905414

The Pharmacokinetics and Haemodynamics of BTS 49 465 and Its Major Metabolite in Healthy Volunteers

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 3905414
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study. BTS 49 465 was rapidly absorbed and cleared from the systemic circulation with a half-life of 1.6 h by oxidation to the sulphone metabolite. The metabolite was cleared with a half-life of 37.6 h. Saliva concentrations of both BTS 49 465 and its metabolite correlated well with the plasma concentrations. Compared to placebo, BTS 49 465 produced statistically significant reductions in blood pressure and increases in heart rate both supine and after a 60 degrees head up tilt. The time course of the haemodynamic changes suggested that the sulphone metabolite contributed to the overall hypotensive response. Plasma Renin Activity was only marginally elevated and there was no evidence of acute fluid retention. BTS 49 465 was well tolerated in terms of haematological and biochemical parameters and subjective side-effects.

Citing Articles

Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.

Thomas P, OGorman D, Sheridan D Br J Clin Pharmacol. 1993; 36(6):539-46.

PMID: 12959270 PMC: 1364658. DOI: 10.1111/j.1365-2125.1993.tb00412.x.


Possible role of metabolite in flosequinan-related mortality.

Kamali F, Edwards C Clin Pharmacokinet. 1995; 29(6):396-403.

PMID: 8787946 DOI: 10.2165/00003088-199529060-00002.


Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Ng H, Walley T, Tsao Y, Breckenridge A Eur J Clin Pharmacol. 1994; 46(4):361-5.

PMID: 7957523 DOI: 10.1007/BF00194406.


Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats.

SIM M, Yates D, Parkinson R, Cooling M Br J Pharmacol. 1988; 94(2):371-80.

PMID: 3293682 PMC: 1854003. DOI: 10.1111/j.1476-5381.1988.tb11539.x.


Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.

Cowley A, Wynne R, Stainer K, Fullwood L, Rowley J, Hampton J BMJ. 1988; 297(6642):169-73.

PMID: 3044507 PMC: 1834251. DOI: 10.1136/bmj.297.6642.169.


References
1.
Ueda H, Yagi S, Kaneko Y . Hydralazine and plasma renin activity. Arch Intern Med. 1968; 122(5):387-91. View

2.
Cowley A, Wynne R, Hampton J . The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. J Hypertens Suppl. 1984; 2(3):S547-9. View